Document Type

Article

Publication Date

6-13-2018

JAX Source

Cell Death Dis 2018 Jun 13; 9(6):705

Volume

9

Issue

6

First Page

705

Last Page

705

ISSN

2041-4889

PMID

29899326

DOI

https://doi.org/10.1038/s41419-018-0705-8

Grant

The Jackson Laboratory Fellowships, the Barbara and Joseph Cohen Foundation, the Partridge Foundation, the Lano Family Foundation, EY11721

Abstract

The cJun N-terminal kinases (JNKs; JNK1, JNK2, and JNK3) promote degenerative processes after neuronal injury and in disease. JNK2 and JNK3 have been shown to promote retinal ganglion cell (RGC) death after optic nerve injury. In their absence, long-term survival of RGC somas is significantly increased after mechanical optic nerve injury. In glaucoma, because optic nerve damage is thought to be a major cause of RGC death, JNKs are an important potential target for therapeutic intervention. To assess the role of JNK2 and JNK3 in an ocular hypertensive model of glaucoma, null alleles of Jnk2 and Jnk3 were backcrossed into the DBA/2J (D2) mouse. JNK activation occurred in RGCs following increased intraocular pressure in D2 mice. However, deficiency of both Jnk2 and Jnk3 together did not lessen optic nerve damage or RGC death. These results differentiate the molecular pathways controlling cell death in ocular hypertensive glaucoma compared with mechanical optic nerve injury. It is further shown that JUN, a pro-death component of the JNK pathway in RGCs, can be activated in glaucoma in the absence of JNK2 and JNK3. This implicates JNK1 in glaucomatous RGC death. Unexpectedly, at younger ages, Jnk2-deficient mice were more likely to develop features of glaucomatous neurodegeneration than D2 mice expressing Jnk2. This appears to be due to a neuroprotective effect of JNK2 and not due to a change in intraocular pressure. The Jnk2-deficient context also unmasked a lesser role for Jnk3 in glaucoma. Jnk2 and Jnk3 double knockout mice had a modestly increased risk of neurodegeneration compared with mice only deficient in Jnk2. Overall, these findings are consistent with pleiotropic effects of JNK isoforms in glaucoma and suggest caution is warranted when using JNK inhibitors to treat chronic neurodegenerative conditions.

Comments

We thank members of the John Laboratory, including Amy Bell and Jocelyn Thomas for technical assistance and help with mouse colony management. We thank Mimi de Vries for helpful discussions and critical reading of the manuscript. We also thank The Jackson Laboratory Scientific Services, especially Electron Microscopy Services including Pete Finger for technical assistance and Histology Services

This open access article is licensed under a Creative Commons Attribution 4.0 International License

Download

Share

COinS